How melanomas bypass new therapy

David Solit and Charles L. Sawyers
Additional contact information
David Solit: David Solit and Charles L. Sawyers are in the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA. sawyersc@mskcc.org
Charles L. Sawyers: David Solit and Charles L. Sawyers are in the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA. sawyersc@mskcc.org

Nature, 2010, vol. 468, issue 7326, 902-903

Abstract: The promise of an exciting new drug that inhibits the mutant B-RAF protein in skin cancer is marred by the fact that most patients relapse within a year. Fresh data hint at how such resistance emerges. See Letters p.968 & p.973

Date: 2010
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/468902a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:468:y:2010:i:7326:d:10.1038_468902a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/468902a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().